Compare CURR & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CURR | CRBU |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.4M | 203.9M |
| IPO Year | N/A | 2021 |
| Metric | CURR | CRBU |
|---|---|---|
| Price | $1.78 | $1.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $3.50 | ★ $9.33 |
| AVG Volume (30 Days) | 229.4K | ★ 981.6K |
| Earning Date | 11-01-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $40,227,053.00 | $9,295,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.56 | $4.96 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.33 | $0.66 |
| 52 Week High | $7.08 | $3.54 |
| Indicator | CURR | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 37.91 | 36.53 |
| Support Level | $1.62 | $1.82 |
| Resistance Level | $1.89 | $1.75 |
| Average True Range (ATR) | 0.22 | 0.10 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 14.81 | 14.49 |
Currenc Group Inc is a fintech pioneer dedicated to transforming financial services through artificial intelligence (AI). It empowers financial institutions with comprehensive AI solutions, including the SEAMLESS AI Call Centre and other AI-powered tools designed to reduce costs, increase efficiency, and boost customer satisfaction. The Company's digital remittance platform also enables e-wallets, remittance companies, and corporations to provide real-time, 24/7 payment services, advancing financial access across underserved communities. It generates the majority of its geographic revenue from Malaysia.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.